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ABSTRACT
Background. Complete cytoreduction with hyperthermic
intraperitoneal chemotherapy (CRS/HIPEC) has been
shown to improve survival in patients with low-grade
mucinous adenocarcinoma (LGMA). However, incomplete
cytoreduction exposes patients to significant morbidity
without a similar survival benefit. Preoperative assessment
of the ability to achieve CRS is therefore a critical step in
selecting patients for CRS/HIPEC.
Objective. The aim of this study was to develop and
validate a preoperative scoring system to accurately predict
the ability to achieve complete cytoreduction in patients
with LGMA of the appendix.
Methods. A simplified preoperative assessment for ap-
pendix tumor (SPAAT) score was developed based on
computed tomography scan findings thought to predict
incomplete cytoreduction. We applied the SPAAT score to
patients with LGMA to determine the ability of the score to
predict complete cytoreduction. This scoring system was
then applied to a separate cohort of patients from a dif-
ferent institution. Sensitivity and specificity were
determined for the SPAAT score. Survival was calculated
and correlated with the SPAAT score and the completeness
of cytoreduction score.
Results. A SPAAT score of\3 is a significant predictor of
complete cytoreduction in the derivation cohort. In the
validation cohort, 40 of 42 patients with a SPAAT score\3
achieved a complete cytoreduction, for a positive predic-
tive value of 95.2 % and a negative predictive value of
100 %. Additionally, the SPAAT score was a significant
predictor of disease-free survival.
Conclusions. The SPAAT score is a useful tool in the
preoperative assessment of patients with LGMA who are
under consideration for cytoreductive surgery. Prospective
analysis of this scoring system is warranted to appropri-
ately select patients who will benefit from CRS/HIPEC.
Appendiceal neoplasms are an uncommon entity, rep-
resenting only 1 % of gastrointestinal malignancies.
Adenocarcinomas represent about two-thirds of appen-
diceal malignancies, and spread of disease can result in
accumulation of mucinous ascites, a clinical symptom
known as pseudomyxoma peritonei.1,2 In such patients,
survival can be significantly improved with appropriate
treatment. Complete cytoreductive surgery (CRS) com-
bined with hyperthermic intraperitoneal chemotherapy
(HIPEC) can result in 5-year survival rates of 30–75 %.3–6
However, this survival benefit is highly dependent on ob-
taining a complete cytoreduction. The completeness of
cytoreduction (CCR) can be characterized by the amount of
remaining disease at the time of CRS/HIPEC. Patients with
no visible disease (CCR0), or disease in which no re-
maining nodule is [2.5 mm (CCR1), have undergone a
complete cytoreduction. Patients who have undergone an
incomplete cytoreduction (CCR2 or 3) obtain significantly
less benefit from the operation.1,7 However, the morbidity
associated with CRS/HIPEC is not trivial, ranging from 28
to 49 %.6,8
Preoperatively identifying which patients are likely to
undergo complete cytoreduction is important to reduce
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morbidity associated with incomplete surgery; however,
preoperatively predicting these patients remains difficult.
Imaging with computed tomography (CT) frequently un-
derstages the amount of disease present.9,10 Magnetic
resonance imaging (MRI) may have some benefit, but the
best outcomes still demonstrate an accuracy of 85 %.11 We
present a novel scoring system, the simplified preoperative
assessment for appendix tumor (SPAAT), which allows for
a preoperative assessment of disease based on high-quality
CT imaging, and predicts the ability to achieve a complete
cytoreduction.
METHODS
All studies were conducted with the approval of the
Institutional Review Board of the University of Texas MD
Anderson Cancer Center (UTMDACC) and NCI Intramu-
ral Program.
Derivation of Simplified Preoperative Assessment for
Appendix Tumor (SPAAT) Score
We developed a set of imaging criteria to predict com-
plete cytoreduction based on preoperative CT Scans in
patients with low-grade mucinous adenocarcinoma
(LGMA) of the appendix treated at our institution (MD
Anderson Cancer Center, Houston, TX, USA). Five ana-
tomic locations were assessed and graded to reflect the
volume and nature of the disease. The presence of scal-
loping was considered to be the important imaging feature;
this feature is identified by the indentation of the organ by
mucinous ascites. One point each was given to the presence
of scalloping on the liver, spleen, pancreas, or portal vein
(Fig. 1). Additionally, 0 or 3 points were assigned to the
absence or presence of mesenteric foreshortening of the
small bowel. In the presence of mucinous ascites, the small
bowel appears to float to the abdominal wall in the absence
of mesenteric foreshortening (Fig. 2a). Once the small
bowel mesentery becomes involved with tumor, the me-
sentery foreshortens, causing the small bowel to appear
tethered and cocoon-like on CT (Fig. 2b), a term known as
‘cauliflowering’ of the small bowel. This score was as-
signed as either a 0 or 3. The SPAAT scoring system
allowed for scores ranging from 0 to 7. All CT scans were
obtained with intravenous contrast.
Derivation Cohort [MD Anderson Cancer Center
(MDACC)]
The CT scans of 30 consecutive patients were evaluated
between June 2008 and June 2009. The SPAAT score was
calculated in a fashion blinded to the outcomes of the case,
FIG. 1 SPAAT scoring of visceral organs. a Mucinous ascites
around the liver and spleen; however, the border is smooth without
evidence of scalloping and this would be assigned zero points. b
Mucinous ascites with a smooth spleen and pancreas border. Again,
zero points are assigned. c CT scan findings of scalloping of the liver
(arrow). d Liver and spleen scalloping (arrows). e Loss of the smooth
pancreatic border with indentation of the organ (arrow), representing
a CT finding that would score one point. SPAAT simplified
preoperative assessment for appendix tumor, CT computed
tomography
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and analysis was subsequently performed to determine
sensitivity and specificity.
Validation Cohort [National Cancer Institute (NCI)]
Patients with LGMA treated at the National Cancer Insti-
tute (NCI) from 1997 to 2005 were identified. Patients with
other histologic diagnoses were not included, and all patients
were treated with the intention of complete cytoreduction and
HIPEC. Radiologic and clinical data were retrospectively
reviewed to identify the CCR, the SPAAT score, complica-
tions, and survival data. SPAAT scores were obtained by
consensus review of two surgeons and two radiologists fa-
miliar with the treatment of patients with peritoneal disease,
who were blinded to the outcome of the operation.
Cytoreduction and Hyperthermic Intraperitoneal
Chemotherapy
Patients at both institutions were treated with complete
CRS involving resection of the entirety of gross disease
and associated visceral resections, as needed.12 Intraperi-
toneal chemotherapy was administered using a closed
technique at temperatures in excess of 40 C. The choice of
chemotherapy was either mitomycin C or cisplatin, and
was determined by practices at each institution. A CCR
score was determined by review of operative and clinical
notes. If not indicated, the score was determined by review
of the details of the operative note.
Statistical Analysis
A true positive was defined as a SPAAT score which pre-
dicted a complete resection. For example, a SPAAT score\3
predicting a CCR0/1 resection would be considered a true
positive, and a SPAAT score\3 in a patient with a CCR2/3
resection would be considered a false positive. A SPAAT
score C3 predicting a CCR2/3 resection would be a true
negative. In this manner, sensitivity, specificity, positive
predictive value (PPV), and negative predictive value (NPV)
were determined for SPAAT scores using cutoff values of 2, 3,
or 4. Sensitivity was defined as the number of patients with
optimal cytoreduction and a SPAAT score\3 (true positives,
n = 40) divided by the total number of patients who had op-
timal cytoreduction (condition positive, n = 40). Specificity
was defined as the number of patients with an incomplete
cytoreduction with a SPAAT score C3 (true negatives,
n = 28) divided by the total number of patients with incom-
plete cytoreduction (condition negative, n = 30). PPV and
NPV were likewise determined by standard methods.
Overall survival (OS) data were calculated using the
date of surgery to the date of last follow-up or death.
Disease-free survival (DFS) was determined using the date
of surgery and the date of first recurrence, while survival
was compared using Kaplan–Meier methods. Prognostic
factors were examined using univariate and multivariable
Cox regression, and categorical variables were compared
using the v2 analysis. Receiver operating curves were
created to estimate the area under the curve. Data were
collected in a database and analyzed using SPSS version 21
software (IBM Corporation, Armonk, NY, USA).
RESULTS
Derivation Cohort (MDACC)
A SPAAT score was determined for 30 patients with
low-grade appendiceal (LGMA) cancers treated with
FIG. 2 SPAAT scoring of the small bowel. Panel a demonstrates a
patient with a significant amount of mucinous ascites, but the small
bowel still appears to be floating freely. This would be assigned a zero
for the SPAAT score. However, in panel b the patient demonstrates
tethering of the small bowel, and would be given 3 points in the
SPAAT system. SPAAT simplified preoperative assessment for
appendix tumor
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attempted CRS/HIPEC at the MDACC from June 2008 to
June 2009. Overall, 27 patients had sufficient data available
for analysis, and SPAAT scores ranged from 0 to 6. We
determined that using a SPAAT score cutoff of 3 identified
23 patients with complete resection and 4 patients with
incomplete resection, for a sensitivity and specificity of
100 %. The various sensitivity and specificity of cutoff
values 2, 3, or 4 are shown in Table 1.
Validation Cohort (NCI)
In an effort to validate the scoring system on a larger
group of patients, external to our institution, we then ap-
plied the scoring system to 70 patients treated at the
surgery branch of the NCI. The median age of patients in
this cohort was 50 years. There were no differences in
demographics with respect to age, sex, ethnicity, or per-
formance status between patients with SPAAT scores\3
versus patients with SPAAT scores C3. Overall, patients
had a good performance status, with 97 % of patients
demonstrating an eastern cooperative oncology group
(ECOG) status of 0. Median follow-up was 52.36 months.
Forty-two patients had a SPAAT score\3, and 28 had a
SPAAT score C3. SPAAT scores ranged from 0 to 7; the
distribution of scores is shown in Fig. 3. Data on sensi-
tivity, specificity, PPV, NPV, and accuracy for SPAAT
values 2, 3, and 4 are shown in Table 1. Using a cutoff of 3,
the SPAAT score showed the greatest sensitivity and
specificity; therefore, for further analysis, the cutoff of a
SPAAT score \3 was used. Next, a receiver operating
characteristic curve was generated for the SPAAT score,
with an area under the curve of 0.947 (95 % confidence
interval 0.874–1.00; p\ 0.001).
For survival analysis, we first analyzed the cohort for the
effect of complete CRS (CCR0 or 1). As depicted in Fig. 4,
we showed that patients with a complete cytoreduction have
improved OS and DFS compared with those with incomplete
cytoreduction. Median OS was 88 ± 14.22 months in the
CCR0/1 group versus 62 ± 11.96 months in the CCR2/3
cohort (p\ 0.05). Median DFS was 32 ± 7.7 months in the
CCR0/1 cohort compared with 10 ± 1 month in the in-
complete cytoreduction group (p\ 0.001). Subsequently,
we then assessed our hypothesis that SPAAT scores would
correlate with survival outcomes. Figure 4 demonstrates a
significant difference in DFS, and a trend toward a differ-
ence in OS, between those patients with a SPAAT score\3
and those with a SPAAT score [3 (DFS: 32 ± 5.3 vs.
10 ± 1 months, p\ 0.001; OS: 88 ± 14.4 vs. 65 ±
12.1 months). There were three 30-day mortalities (4.3 %),
all in patients with a SPAAT score[3. Significant compli-
cations (Clavien 2, 3, 4) were not statistically different
between groups, although were more common in the group
with a SPAAT score C3 (34.6 % compared with 23 % in the
group with a SPAAT score\3).
DISCUSSION
In this study, we demonstrated a simple preoperative
scoring system that accurately predicts the ability to obtain
complete cytoreduction in patients with LGMA. The
scoring system is based on high-quality CT imaging and











Derivation cohort (n = 27)
SPAAT C 2 100 36.4 69.6 100 0.503
SPAAT C 3 100 100 100 100 1.0
SPAAT C 4 92 100 100 50 0.678
Validation cohort (n = 70)
SPAAT C 2 62.5 93.3 92.6 65.1 0.568
SPAAT C 3 100 93.3 95.2 100 0.943
SPAAT C 4 100 70 81.6 100 0.756
NPV negative predictive value, PPV positive predictive value, SPAAT
simplified preoperative assessment for appendix tumor
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FIG. 3 Distribution of SPAAT scores
in the validation cohort (n = 70).
Scores in the validation cohort ranged
from 0 to 7. Overall, 42 patients (60 %)
demonstrated an SPAAT score\3, and
28 (40 %) had scores C3. SPAAT
simplified preoperative assessment for
appendix tumor
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because of the association with complete cytoreduction, the
SPAAT also correlates with survival outcomes. The im-
portance of complete cytoreduction has been demonstrated
in several studies.1,4,13 For example, Chua et al. reviewed
over 2000 patients with appendiceal cancer from multiple
institutions, and demonstrated a 24 % 5-year survival with
incomplete cytoreduction compared with approximately
80 % for patients undergoing a CCR0/1 resection.1
Similarly, Baratti et al. showed a significant difference in
both OS and DFS for patients undergoing incomplete cy-
toreduction.13 Our results showing a 5-year OS of 72.6 %
in patients undergoing a complete cytoreduction are in line
with these previous reports and demonstrate the importance
of patient selection for surgery as incomplete cytoreduction
has less benefit for patients. Our results for morbidity are
also within published ranges. Thus, our model of predicting
those patients most likely to achieve complete cytoreduc-
tion would appear to lead to the most clinical benefit, while
minimizing morbidity.
It is important to note that our scoring system is a
marker of overall disease severity rather than a predictor of
where a patient will fail. There is a more direct correlation
of small-bowel tethering and unresectable disease, thus the
higher score for this finding. However, scalloping of the
spleen leading to the assignment of a point on our scoring
system does not suggest a patient is likely to fail in the left
upper quadrant (as the spleen is easily resected in situations
of significant disease). However, this is a preoperative
marker of the extent, and possibly the aggressiveness, of
disease one will encounter upon exploration. Likewise, our
scoring system does not assign points for disease in the
pelvis. This is not to suggest patients do not fail in the
pelvis, but rather that we have not found imaging charac-
teristics that predict the inability to achieve complete
cytoreduction.
A scoring system somewhat similar to the SPAAT score
has been developed for patients with advanced ovarian
cancer. This system, designated the predictive index value
(PIV) is based on laparoscopic evaluation of eight ana-
tomic locations.14,15 A score C8 is an accurate predictor of
the inability to achieve complete cytoreduction. We have
developed our score using preoperative imaging with the
intention of sparing the complications associated with la-
paroscopy. Our ability to predict those patients who will
achieve complete cytoreduction is higher than that
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FIG. 4 Complete cytoreduction is associated with improved OS and
DFS. a OS is significantly higher in patients with complete
cytoreduction compared with those with incomplete cytoreduction.
b Patients with SPAAT scores \3 demonstrated improved OS
compared with those with an SPAAT score C3; however, this did not
reach statistical significance. c DFS was compared in the validation
cohort between patients with a complete cytoreduction and those
without. The median DFS was significantly longer in patients with
CCR0/1 resection (p\ 0.001). d DFS for patients based on SPAAT
score. The survival curves for patients with CCR1/2 resection are
nearly identical to those with an SPAAT score\3. CCR completeness
of cytoreduction, DFS disease-free survival, OS overall survival,
SPAAT simplified preoperative assessment for appendix tumor
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We currently use the SPAAT score as an adjunct in the
decision-making process for patients with LGMA. A
SPAAT score C3 is not an absolute contraindication to
operation; however, it is valuable to be able to set expec-
tations prior to the operation. An incomplete cytoreduction
may still benefit the patient with relief of symptoms, but
the survival benefit is significantly less than for those pa-
tients with a complete cytoreduction.1,16 The SPAAT score
allows for preoperative discussions to focus on the intent of
operation, i.e., palliative versus intent for complete cy-
toreduction. Patients with significant comorbidities and a
SPAAT score C3 would likely be counseled that the risks
of operation outweigh the benefits. The converse is also
true. Thus, a patient with mild to moderate comorbid
conditions and with a SPAAT score\3 is likely to achieve
complete cytoreduction and the survival benefit associated
with such. Hence, an aggressive approach to operation may
be warranted in this setting.
The limitations of our study include the retrospective
nature of the data collection and the associated limitations
of such studies. At the time of the study, we did not have
consistent use of preoperative tumor markers to correlate
the carbohydrate antigen (CA) 19-9, carcinogenic embry-
onic antigen, or CA-125 levels with imaging findings.
Additionally, we only included patients with an excellent
performance status (97 % ECOG 0). It is our practice, and
that of others, to be highly selective with regard to offering
CRS/HIPEC, but this limits the applicability of the scoring
system to less fit patients. Most notably, the designation of
a complete cytoreduction is based on leaving no visible
disease [2.5 mm in size. This is somewhat subjective as
not every site of disease is measured. As such, this may
lead to bias as surgeons may have been more likely to
designate a resection as CCR2 in the setting of more ad-
vanced disease on preoperative imaging. However, this was
the rationale for the validation cohort. In this cohort, the
CCR scores were derived independently of knowledge of
the SPAAT score. We included only LGMA patients in this
analysis. The SPAAT score should not be generalized to
patients with high-grade appendiceal cancer at this time.
CONCLUSIONS
Our data showed that the SPAAT score can reliably be
obtained from high-quality preoperative CT scan. Using a
cutoff of \3 points, we demonstrated an accuracy of
97.14 % in determining which patients would undergo a
complete cytoreduction. As CCR is the predominant factor
determining treatment success in patients with LGMA, we
suggest that this scoring system can be useful in the pre-
operative decision-making process. Prospective trials
utilizing the SPAAT score are warranted.
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